At study entry, canonical markers of an inflamed tumor microenvironment (TME), such as PD-L1 protein and gene expression and CD3+ and CD8+ T cell density in tumor stroma and tumor nests, were lower in patients in the tobemstomig arm versus the nivolumab plus ipilimumab arm (Fig. 2a,b and Extended Data Fig. 3). The gene discussed is CD274; the disease is neoplasm.